Literature DB >> 20333482

ABC transporters as molecular effectors of pancreatic oncogenic pathways: the Hedgehog-GLI model.

Marta Santisteban1.   

Abstract

INTRODUCTION: Chemoresistance is the main cause of disease progression and mortality among patients diagnosed from pancreatic adenocarcinoma. Nowadays, most patients are diagnosed with advanced disease, and chemotherapy becomes the corner stone of care, looking for clinical benefit and improvement in survival. However, response rates are low, and disease outcome is very short, needing for new drugs that overcome resistance.
BACKGROUND: Till date, one of the better known mechanisms of drug resistance in cancer is related to ATP-binding cassette (ABC) transporters, highly expressed in solid tumors and, moreover, in cancer stem cells. These cancer stem cells are thought to be responsible for tumor maintenance, progression, and relapse of the disease due, in part, to an exhibition of multiple resistance mechanisms to chemotherapy and radiation.
PURPOSE: In order to remove this cancer stem cell population within the tumors, it is imperative to look for new molecular pathways involved in pancreatic carcinogenesis and stemness. In this study, we suggest a potential role of hedgehog-GLI pathway in pancreatic cancer chemoresistance, based on ABC transporters' overexpression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20333482     DOI: 10.1007/s12029-010-9144-1

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  40 in total

Review 1.  The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research.

Authors:  Michael M Gottesman; Victor Ling
Journal:  FEBS Lett       Date:  2005-12-28       Impact factor: 4.124

2.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.

Authors:  Asma Sultana; Catrin Tudur Smith; David Cunningham; Naureen Starling; John P Neoptolemos; Paula Ghaneh
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

3.  Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis.

Authors:  Jennifer P Morton; Michelle E Mongeau; David S Klimstra; John P Morris; Yie Chia Lee; Yoshiya Kawaguchi; Christopher V E Wright; Matthias Hebrok; Brian C Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

Review 4.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

Review 5.  Targeted therapy for cancer stem cells: the patched pathway and ABC transporters.

Authors:  H Lou; M Dean
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

Review 6.  ABC multidrug transporters: structure, function and role in chemoresistance.

Authors:  Frances J Sharom
Journal:  Pharmacogenomics       Date:  2008-01       Impact factor: 2.533

Review 7.  Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.

Authors:  Macus Tien Kuo
Journal:  Antioxid Redox Signal       Date:  2009-01       Impact factor: 8.401

Review 8.  Primers on molecular pathways GLI: more than just Hedgehog?

Authors:  Martín E Fernández-Zapico
Journal:  Pancreatology       Date:  2008-05-22       Impact factor: 3.996

9.  Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.

Authors:  Maria-Theresa Mueller; Patrick C Hermann; Juliane Witthauer; Belen Rubio-Viqueira; Simon F Leicht; Stephan Huber; Joachim W Ellwart; Mona Mustafa; Peter Bartenstein; Jan G D'Haese; Michael H Schoenberg; Frank Berger; Karl-Walter Jauch; Manuel Hidalgo; Christopher Heeschen
Journal:  Gastroenterology       Date:  2009-06-06       Impact factor: 22.682

10.  A paracrine requirement for hedgehog signalling in cancer.

Authors:  Robert L Yauch; Stephen E Gould; Suzie J Scales; Tracy Tang; Hua Tian; Christina P Ahn; Derek Marshall; Ling Fu; Thomas Januario; Dara Kallop; Michelle Nannini-Pepe; Karen Kotkow; James C Marsters; Lee L Rubin; Frederic J de Sauvage
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

View more
  8 in total

1.  Evidence for epithelial-mesenchymal transition in cancer stem-like cells derived from carcinoma cell lines of the cervix uteri.

Authors:  Jiaying Lin; Xishi Liu; Ding Ding
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 2.  Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters.

Authors:  Patricia Dauer; Alice Nomura; Ashok Saluja; Sulagna Banerjee
Journal:  Pancreatology       Date:  2016-12-23       Impact factor: 3.996

Review 3.  Role of GLI Transcription Factors in Pathogenesis and Their Potential as New Therapeutic Targets.

Authors:  Maja Sabol; Diana Trnski; Vesna Musani; Petar Ozretić; Sonja Levanat
Journal:  Int J Mol Sci       Date:  2018-08-29       Impact factor: 5.923

4.  The effects of growth hormone on therapy resistance in cancer.

Authors:  Reetobrata Basu; John J Kopchick
Journal:  Cancer Drug Resist       Date:  2019-09-19

5.  Membrane drug transporters and chemoresistance in human pancreatic carcinoma.

Authors:  Wolfgang Hagmann; Ralf Faissner; Martina Schnölzer; Matthias Löhr; Ralf Jesnowski
Journal:  Cancers (Basel)       Date:  2010-12-30       Impact factor: 6.639

Review 6.  The roles of FOXM1 in pancreatic stem cells and carcinogenesis.

Authors:  Ming Quan; Peipei Wang; Jiujie Cui; Yong Gao; Keping Xie
Journal:  Mol Cancer       Date:  2013-12-10       Impact factor: 27.401

7.  Identification and causes of metabonomic difference between orthotopic and subcutaneous xenograft of pancreatic cancer.

Authors:  Bohan Zhan; Shi Wen; Jie Lu; Guiping Shen; Xianchao Lin; Jianghua Feng; Heguang Huang
Journal:  Oncotarget       Date:  2017-05-22

8.  Biological responses to core-shell-structured Fe3O4@SiO2-NH2 nanoparticles in rats by a nuclear magnetic resonance-based metabonomic strategy.

Authors:  Zhongxue Yuan; Rui Xu; Jinquan Li; Yueli Chen; Binghui Wu; Jianghua Feng; Zhong Chen
Journal:  Int J Nanomedicine       Date:  2018-04-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.